Remove DNA Remove Genome Remove Medicine
article thumbnail

Hopewell Therapeutics raises funds for genomic medicines development

Pharmaceutical Technology

Biotechnology company Hopewell Therapeutics has raised $25m in seed financing to accelerate the development of next-generation lipid nanoparticles for targeted delivery of genomic medicines. Hopewell Therapeutics is engaged in discovering, synthesising and developing advanced ttLNPs to provide next-generation genomic medicines.

Genome 130
article thumbnail

The future of genomic medicine: can it fulfil its promises?

pharmaphorum

Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential. I saw this, in particular, with the finishing of the human genome,” says Charlie. “At At that time, we thought this would be the holy grail for medicine.

Genome 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The pangenome is making personalised medicine more equitable

Pharmaceutical Technology

Basic human traits such as eye and hair colour are determined by our DNA. metres of supercoiled DNA contained within its nucleus. If you were to uncoil all the DNA in your body into a single continuous strand it would be 54 trillion metres in length, enough to stretch from the Earth to the Sun and back 180 times.

article thumbnail

Nobel Prize in medicine awarded for research into the evolutionary history of humankind

STAT News

A Swedish scientist won the 2022 Nobel Prize in medicine or physiology on Monday for his groundbreaking research into the evolutionary history of humankind. Pääbo unlocked scientists’ understanding of how genes from these extinct relatives have been passed down to present-day humans.

Medicine 142
article thumbnail

Blacksmith Medicines to merge with Forge Therapeutics

Pharmaceutical Technology

Blacksmith Medicines has signed a definitive merger agreement with Forge Therapeutics to create a combined entity that will discover and develop medicines targeting a large class of proteins called metalloenzymes. The merged entity will focus on developing medicines with an initial focus on oncology and infection.

Medicine 130
article thumbnail

Oncotarget: Genome wide DNA methylation landscape reveals glioblastoma’s influence

Scienmag

These Oncotarget results suggest that GBM might induce epigenetic alterations in tumor infiltrating CD4 T-cells Credit: Correspondence to – Mahua Dey – dey@neurosurgery.wisc.edu Oncotarget published “Genome wide DNA methylation landscape reveals glioblastoma’s influence on epigenetic changes in tumor infiltrating CD4+ T cells” (..)

Genome 73
article thumbnail

Opinion: A better understanding of human diversity is needed to equitably advance precision medicine

STAT News

Precision medicine — tailoring a treatment to an individual’s disease — requires understanding the individual’s biological characteristics. More than 80% of genomics studies have been conducted in people of European descent. Read the rest…

Medicine 111